Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comprehensive serum biomarker analysis reveals IL-8 changes as the only predictor of the effectiveness of immune checkpoint inhibitors for patients with advanced non-small cell lung cancer.
Akamatsu H, Koh Y, Nishio M, Goto Y, Hayashi H, Miura S, Tamada K, Kagamu H, Gemma A, Yoshino I, Misumi T, Mouri A, Saito R, Takase N, Yanagitani N, Nokihara H, Seike M, Takamura K, Mori M, Iwasawa S, Nakagawa S, Mitsudomi T. Akamatsu H, et al. Among authors: misumi t. Lung Cancer. 2024 Nov 9;198:108017. doi: 10.1016/j.lungcan.2024.108017. Online ahead of print. Lung Cancer. 2024. PMID: 39571250 Free article.
Predictors of tolerability for postoperative adjuvant S1 plus docetaxel chemotherapy for gastric cancer: a multicenter retrospective study.
Toyota K, Tanabe K, Kano M, Komo T, Hotta R, Yanagawa S, Saeki Y, Tazawa H, Ikeda M, Shishida M, Okano K, Ide R, Imaoka Y, Takahashi S, Ohdan H; Hiroshima Surgical Study Group of Clinical Oncology (HiSCO). Toyota K, et al. Gastric Cancer. 2024 Nov 9. doi: 10.1007/s10120-024-01563-w. Online ahead of print. Gastric Cancer. 2024. PMID: 39520590
Association between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.
Hayashi H, Nishio M, Akamatsu H, Goto Y, Miura S, Gemma A, Yoshino I, Misumi T, Kijima T, Takase N, Fujita M, Tasaka S, Mouri A, Kondo T, Takamura K, Kawashima Y, Imaizumi K, Iwasawa S, Nakagawa S, Mitsudomi T. Hayashi H, et al. Among authors: misumi t. Cancer Res Commun. 2024 Nov 1;4(11):2858-2867. doi: 10.1158/2767-9764.CRC-24-0212. Cancer Res Commun. 2024. PMID: 39392339 Free PMC article.
Prognostic risk score and index including the platelet-to-lymphocyte ratio and lactate dehydrogenase in patients with metastatic or unresectable urothelial carcinoma treated with immune checkpoint inhibitors.
Kobayashi K, Sakano S, Matsumoto H, Yamamoto M, Tsuchida M, Tei Y, Nagao K, Oba K, Kitahara S, Yano S, Yoshihiro S, Yamamoto Y, Ohmi C, Komatsu H, Misumi T, Akao J, Shiraishi K. Kobayashi K, et al. Among authors: misumi t. Jpn J Clin Oncol. 2024 Oct 7:hyae137. doi: 10.1093/jjco/hyae137. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 39373462
ctDNA-based molecular residual disease and survival in resectable colorectal cancer.
Nakamura Y, Watanabe J, Akazawa N, Hirata K, Kataoka K, Yokota M, Kato K, Kotaka M, Kagawa Y, Yeh KH, Mishima S, Yukami H, Ando K, Miyo M, Misumi T, Yamazaki K, Ebi H, Okita K, Hamabe A, Sokuoka H, Kobayashi S, Laliotis G, Aushev VN, Sharma S, Jurdi A, Liu MC, Aleshin A, Rabinowitz M, Bando H, Taniguchi H, Takemasa I, Kato T, Kotani D, Mori M, Yoshino T, Oki E. Nakamura Y, et al. Among authors: misumi t. Nat Med. 2024 Nov;30(11):3272-3283. doi: 10.1038/s41591-024-03254-6. Epub 2024 Sep 16. Nat Med. 2024. PMID: 39284954 Free PMC article.
Comparative Efficacy of Avelumab Maintenance Therapy Versus Continued Chemotherapy Followed by Pembrolizumab in Metastatic Urothelial Carcinoma With No Progression After 4 Cycles of Chemotherapy: A Retrospective Study Using Propensity Score Matching.
Kobayashi K, Matsumoto H, Sakano S, Yamamoto M, Tsuchida M, Tei Y, Nagao K, Oba K, Kitahara S, Yano S, Yoshihiro S, Yamamoto Y, Ohmi C, Komatsu H, Misumi T, Akao J, Shiraishi K. Kobayashi K, et al. Among authors: misumi t. Clin Genitourin Cancer. 2024 Aug 23;22(6):102212. doi: 10.1016/j.clgc.2024.102212. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 39270620
Real-World Pharmacokinetics, Effectiveness, and Safety of Atezolizumab in Patients With Unresectable Advanced or Recurrent NSCLC: An Exploratory Study of J-TAIL.
Yagishita S, Goto Y, Nishio M, Akamatsu H, Hayashi H, Miura S, Tamada K, Kagamu H, Hamada A, Ohuchi M, Gemma A, Yoshino I, Misumi T, Hata A, Hara S, Kijima T, Masaki F, Iwasawa S, Nakagawa S, Tatsuno M, Mitsudomi T. Yagishita S, et al. Among authors: misumi t. JTO Clin Res Rep. 2024 May 16;5(7):100683. doi: 10.1016/j.jtocrr.2024.100683. eCollection 2024 Jul. JTO Clin Res Rep. 2024. PMID: 39091595 Free PMC article.
QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC.
Bando H, Kotani D, Satake H, Hamaguchi T, Shiozawa M, Kotaka M, Masuishi T, Yasui H, Kagawa Y, Komatsu Y, Oki E, Yamamoto Y, Kawakami H, Misumi T, Taniguchi H, Yamazaki K, Muro K, Yoshino T, Kato T, Tsuji A. Bando H, et al. Among authors: misumi t. Med. 2024 Sep 13;5(9):1164-1177.e3. doi: 10.1016/j.medj.2024.05.012. Epub 2024 Jun 19. Med. 2024. PMID: 38901425 Free article. Clinical Trial.
204 results